Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03883581 · ClinicalTrials.gov registry record · Phase 1
Impact of Nuedexta on Bulbar Physiology and Function in ALS
A Phase 1 study of Amyotrophic Lateral Sclerosis, sponsored by University of Florida.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT03883581 is a Phase 1 study of Amyotrophic Lateral Sclerosis that has completed, run by University of Florida. The registered enrollment target is 28 participants, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03883581, a Phase 1 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
Nuedexta is FDA approved for the treatment of pseudobulbar affect in ALS patients and anecdotal reports of improvements in speech, salivation or swallowing have been reported. However, no prospective study has been conducted to comprehensively examine and determine the physiologic impact of Nuedexta on both speech and swallowing physiology in a large group of ALS individuals. These data are needed in order to provide evidence-based guidance to the management of bulbar dysfunction in ALS.
Conditions Studied
Interventions
- DRUG dextromethorphan HBr and quinidine sulfate
Study Locations (2)
Florida
- Phil Smith Neuroscience Institute at Holy Cross Hospital - Fort Lauderdale
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2021-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03883581
The ClinicalTrials.gov registry entry for NCT03883581 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (97% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which dextromethorphan HBr and quinidine sulfate is the first listed.
NCT03883581 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03883581 about?
NCT03883581 is a clinical study titled "Impact of Nuedexta on Bulbar Physiology and Function in ALS". Nuedexta is FDA approved for the treatment of pseudobulbar affect in ALS patients and anecdotal reports of improvements in speech, salivation or swallowing have been reported. However, no prospective study has been conducted to comprehensively examine and determine the physiologic impact of Nuedexta...
What is the current status of trial NCT03883581?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2019-07-25. Estimated completion is 2021-11-22.
What conditions does trial NCT03883581 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT03883581?
The interventions under investigation include: dextromethorphan HBr and quinidine sulfate (DRUG).
Who is sponsoring clinical trial NCT03883581?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03883581 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS
RECRUITING · Phase 1
-
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
RECRUITING · Phase 1
-
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
ACTIVE NOT RECRUITING · Phase 1
-
Regulatory T Cells for Amyotrophic Lateral Sclerosis
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.